Last reviewed · How we verify
Rotavirus vaccine (BRV-PV)
BRV-PV is a live attenuated rotavirus vaccine that stimulates immune responses to prevent rotavirus gastroenteritis.
BRV-PV is a live attenuated rotavirus vaccine that stimulates immune responses to prevent rotavirus gastroenteritis. Used for Prevention of rotavirus gastroenteritis in infants and young children.
At a glance
| Generic name | Rotavirus vaccine (BRV-PV) |
|---|---|
| Sponsor | Epicentre |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains weakened rotavirus strains that replicate in the intestinal tract, triggering both humoral and mucosal immune responses without causing severe disease. This primes the immune system to recognize and neutralize wild-type rotavirus upon natural exposure, preventing infection or reducing disease severity.
Approved indications
- Prevention of rotavirus gastroenteritis in infants and young children
Common side effects
- Diarrhea
- Vomiting
- Fever
- Irritability
Key clinical trials
- Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger (PHASE3)
- Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization (PHASE3)
- A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants (PHASE3)
- Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rotavirus vaccine (BRV-PV) CI brief — competitive landscape report
- Rotavirus vaccine (BRV-PV) updates RSS · CI watch RSS
- Epicentre portfolio CI